Healthcare / Medical DistributionNasdaqGM
$4.13
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$155M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-150.7%
↓Gross Margin
42.5%
↓Debt/Equity
0.82
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+1.6%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $70.5M · net income $-29.2M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $70.5M | $70.5M | $69.4M |
| Net Income | $-29.2M | $-29.2M | $-20.6M |
| EBITDA | $-21.3M | $-21.3M | $-19.4M |
| EPS | -0.78 | -0.78 | -0.55 |
| Gross Margin | 42.5% | 42.5% | 41.4% |
| Operating Margin | -35.0% | -35.0% | -32.0% |
| Net Margin | -41.5% | -41.5% | -29.7% |
| Balance Sheet | |||
| Debt/Equity | 0.82 | 0.82 | 0.05 |
| Returns | |||
| ROE | -150.7% | -150.7% | -48.5% |
| Growth & Yield | |||
| Revenue Growth | 1.6% | 1.6% | — |
| EPS Growth | -41.8% | -41.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.